Market›Health Care›Biotechnology›Biotechnology
ASCLETIS PHARMA INC

ASCLF

$2.36Apr 28, 2021 – Apr 27, 2026
Health CareBiotechnology$2.47B
MVM
-$59.1M
TD Variance
-5.357

Every news event mapped to its market reaction — 20 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-04-07+13.4%newsPR NewswireAscletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
2026-03-01-10.1%newsMarketBeatSagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
2026-02-19+6.9%newsSimply Wall St.Ascletis Pharma’s ASC36 Obesity Move Meets Strong Share Price Momentum
2026-02-10+6.3%newsPR NewswireAscletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
2025-03-07+3.9%newsSeeking AlphaSagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha
2023-01-17+3.7%expansionSeeking AlphaSupply enters ritonavir tablets supply agreement with Simcere
2026-03-11+1.6%newsGlobeNewswireSagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
2022-04-19-1.5%newsSeeking AlphaAscletis ASC11 preclinical data shows promise as potential therapy for COVID-19
2026-04-24+1.5%newsMSNCentessa is the top-performing foreign healthcare stock YTD - MSN
2026-03-25+1.2%earningsInsider MonkeyAnalysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results
2022-07-13+0.8%newsSeeking AlphaCould Covid Drugs Help Cure Financial Ills At Ascletis Pharma?
2022-12-07-0.6%newsSeeking AlphaAscletis gets Chinese drug regulator nod to start trial of oral COVID therapy
2026-04-09-0.5%legalSimply Wall St.A Look At Ascletis Pharma SEHK:1672 Valuation After ASC30_39 Obesity Candidate Advances Toward US FDA IND
2026-03-10-0.5%newsPR NewswireAscletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
2025-12-15+0.4%newsYahoo FinanceAscletis Pharma (SEHK:1672): Reassessing Valuation After a Sharp One-Day Pullback and Powerful 12-Month Rally - Yahoo Finance
2021-08-25+0.4%newsSeeking AlphaAscletis commences Phase II trial of ASC42 in China for chronic hepatitis B
2023-01-03-0.3%legalSeeking AlphaViking Therapeutics sues Ascletis Pharma for stealing trade secrets
2026-01-29+0.2%newsSeeking AlphaSagimet down as Chinese partner posts late-stage trial data for acne therapy
2026-02-15-0.2%newsMarketBeatSagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference
2026-04-27—newsPR NewswireAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
tickerdossier.comtickerdossier.substack.com